Company intelligence / Profile preview
Nectid
Princeton, New Jersey, United Statesnectid.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Nectid has initiated clinical development for drugs targeting autism and pain. Its lead program NFX‑21 is in the clinical stage for nonalcoholic steatohepatitis. The company has a history of patent sales to major pharmaceutical companies and focuses on repurposing known drugs for CNS disorders.
- Therapeutic areas
- GastroenterologyPsychiatryNeurology
- Modalities
- Small moleculeDrug delivery platform
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Grunenthal GmbH acquired part of the pain patent portfolio from Nectid in March 2010–2012 period. No other major partnerships disclosed publicly.
Beyond the preview
Go deeper on Nectid.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nectid.